Spherix Global Insights recently released its latest findings from RealTime Dynamix™: Paroxysmal Nocturnal Hemoglobinuria Q1 2025 (US) an independent tracking study based on insights from 51 U.S.

Michael Bromberg, MD, PhD, talks with Physician’s Weekly about renal disease in patients with paroxysmal nocturnal ...

DelveInsight's "EMPAVELI Market Size, Forecast, and Market Insight Report" highlights the details around EMPAVELI, a ...

EMPAVELI's unique mechanism of targeting C3 broadens its applicability beyond PNH, including other complement-driven diseases like geographic atrophy and immune complex-mediated diseases. With ...

I am 71, and I recently saw my urologist for urinating a lot and not getting enough sleep. He performed a flow test and a ...

Anemia of chronic disease is caused by long-term underlying health conditions, such as autoimmune disorders, that affect your body’s ability to make red blood cells. If you have anemia, you have ...

Apellis Pharma and partner Sobi have won EU approval for their paroxysmal nocturnal haemoglobinuria (PNH) drug pegcetacoplan in Europe, with a more restricted label than in the US. The European ...

In the developed world, most of the reported complications of transfusion have an immunological basis. Although the media and the public are worried about the infectious risks of transfusion ...

When acetazolamide, an agent used to treat hyperkalemic periodic paralysis, was inadvertently found to relieve a patient with the hypokalemic variety, he and another patient were observed to ...